| Literature DB >> 25324420 |
Anne Makena1, Jürgen Brem1, Inga Pfeffer1, Rebecca E J Geffen1, Sarah E Wilkins1, Hanna Tarhonskaya1, Emily Flashman1, Lynette M Phee2, David W Wareham2, Christopher J Schofield3.
Abstract
OBJECTIVES: Metallo-β-lactamase (MBL)-based resistance is a threat to the use of most β-lactam antibiotics. Multiple variants of the New Delhi MBL (NDM) have recently been reported. Previous reports indicate that the substitutions affect NDM activity despite being located outside the active site. This study compares the biochemical properties of seven clinically reported NDM variants.Entities:
Keywords: antibiotic resistance; carbapenemases; cephalosporins; thermal stability; β-lactams
Mesh:
Substances:
Year: 2014 PMID: 25324420 PMCID: PMC4291237 DOI: 10.1093/jac/dku403
Source DB: PubMed Journal: J Antimicrob Chemother ISSN: 0305-7453 Impact factor: 5.790
Figure 1.View from an NDM-1 crystal structure with hydrolysed methicillin (PDB code: 4EY2) showing the positions of the identified substitutions relative to the active site: NDM-3, D95N; NDM-4, M154L; NDM-5, V88L and M154L; NDM-6, A233V; NDM-7, D130N and M154L; and NDM-8, D130G and M154L. Pink spheres indicate the two zinc ions.
Susceptibility of E. coli transformed with plasmids containing NDM variants
| Host strain | Plasmida | MIC determined by Etest (mg/L) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| AMP | CEF | FOX | CAZ | ERT | IMP | DOR | MEM | ||
| pCR2.1 | 4 | 0.008 | 0.008 | 0.125 | 0.008 | 0.25 | 0.032 | 0.047 | |
| pCR2.1 NDM-1 | >256 | >256 | 24 | >256 | 0.38 | 0.38 | 0.25 | 0.38 | |
| pCR2.1 NDM-1 P+ | >256 | >256 | >256 | >256 | 8 | 8 | 8 | 4 | |
| pCR2.1 NDM-2 | >256 | >256 | >256 | >256 | 2 | 0.38 | 0.38 | 0.38 | |
| pCR2.1 NDM-2 P+ | >256 | >256 | >256 | >256 | 16 | 8 | 8 | 4 | |
| pHSG398/NDM-3b | 256 | NA | 32 | 256 | NA | 0.25 | 0.125 | 0.25 | |
| pCR2.1 NDM-4 | >256 | >256 | >256 | >256 | 2 | 0.25 | 0.032 | 0.38 | |
| pCR2.1 NDM-4 P+ | >256 | >256 | >256 | >256 | 16 | >32 | 12 | 8 | |
| pCR2.1 NDM-5 | >256 | >256 | >256 | >256 | 2 | 0.25 | 0.5 | 0.38 | |
| pCR2.1 NDM-5 P+ | >256 | >256 | >256 | >256 | >32 | >32 | 12 | >32 | |
| pCR2.1 NDM-6 | >256 | >256 | >256 | >256 | 1 | 0.38 | 0.125 | 0.38 | |
| pCR2.1 NDM-6 P+ | >256 | >256 | >256 | >256 | >32 | 8 | 1.5 | >32 | |
| pCR2.1 NDM-7 | >256 | >256 | >256 | 32 | 2 | 2 | 0.5 | 1 | |
| pCR2.1 NDM-7 P+ | >256 | >256 | >256 | >256 | >32 | >32 | 8 | >32 | |
| pHSG398/NDM-8b | 256 | NA | 64 | 256 | NA | 0.5 | NA | 0.25 | |
AMP, ampicillin; CEF, cefalotin; FOX, cefoxitin; CAZ, ceftazidime; ERT, ertapenem; IMP, imipenem; DOR, doripenem; MEM, meropenem; NA, not available.
aP+ indicates plasmids containing the native ISAba125 promoter.
bData from Tada et al.[21,24] MICs determined by broth microtitre dilution.
Figure 2.Clinically observed substitutions alter the stability of NDM variants. (a) Normalized CD spectra of NDM variants. (b) Thermal stability melting curves. (c) Melting temperatures of the NDM variants as determined by CD: NDM-1, 59.5 ± 0.1; NDM-3, 63.4 ± 0.1; NDM-4, 61.4 ± 0.2; NDM-5, 64.6 ± 0.3; NDM-6, 55.1 ± 0.3; NDM-7, 64.6 ± 0.2; and NDM-8, 72.1 ± 0.4. Data are the means of triplicate experiments, with error bars showing the standard deviation (±SD).
Kinetic parameters of seven NDM variants with representative β-lactam antibiotics
| Antibiotic | NDM-1 | NDM-3 | NDM-4 | NDM-5 | NDM-6 | NDM-7 | NDM-8 |
|---|---|---|---|---|---|---|---|
| Carbapenems | |||||||
| imipenem | |||||||
| | 78 ± 4 | 82 ± 12 | 62 ± 8 | 148 ± 16 | 62 ± 6 | 56 ± 6 | 20 ± 3 |
| | 600 | 757 | 252 | 332 | 355 | 127 | 54 |
| | 7.6 | 9.2 | 4.1 | 2.2 | 5.8 | 2.3 | 2.9 |
| meropenem | |||||||
| | 57 ± 9 | 58 ± 11 | 119 ± 9 | 99 ± 4 | 49 ± 4 | 45 ± 5 | 54 ± 5 |
| | 301 | 238 | 583 | 413 | 362 | 194 | 141.7 |
| | 5.2 | 4.2 | 4.9 | 4.1 | 7.4 | 4.3 | 2.6 |
| doripenem | |||||||
| | 119 ± 17 | 83 ± 15 | 125 ± 10 | 126 ± 11 | 119 ± 18 | 64 ± 11 | 151 ± 9 |
| | 226 | 170 | 743 | 570 | 1032 | 348 | 267.4 |
| | 1.9 | 2.0 | 6.0 | 4.5 | 8.6 | 5.4 | 1.7 |
| Penicillins | |||||||
| ampicillin | |||||||
| | 110 ± 23 | 258 ± 54 | 305 ± 48 | 156 ± 20 | 455 ± 69 | 207 ± 55 | 229 ± 45 |
| | 447 | 724 | 900 | 408 | 1375 | 477 | 273 |
| | 4.1 | 2.8 | 2.9 | 2.6 | 3.0 | 2.3 | 1.2 |
| Cephalosporins | |||||||
| cefalotin | |||||||
| | 29 ± 6 | 13 ± 3 | 11 ± 2 | 15 ± 3 | 10 ± 2 | 11 ± 3 | 5 ± 1 |
| | 75 | 53 | 45 | 25 | 63 | 18 | 9 |
| | 2.6 | 4.6 | 4.1 | 1.6 | 6.1 | 1.5 | 1.9 |
| cefoxitin | |||||||
| | 43 ± 6 | 50 ± 6 | 63 ± 7 | 27 ± 5 | 107 ± 9 | 23 ± 3 | 16 ± 3 |
| | 10 | 6 | 14 | 4 | 18 | 4 | 3 |
| | 0.23 | 0.13 | 0.22 | 0.14 | 0.17 | 0.15 | 0.18 |
| ceftazidime | |||||||
| | 100 ± 19 | 115 ± 15 | 133 ± 18 | 86 ± 11 | 144 ± 25 | 79 ± 10 | 19 ± 5 |
| | 24 | 23 | 28 | 15 | 29 | 16 | 5 |
| | 0.23 | 0.20 | 0.21 | 0.18 | 0.20 | 0.20 | 0.26 |
| nitrocefin | |||||||
| | 11 ± 2 | 4 ± 1 | 4 ± 1 | 6 ± 1 | 8 ± 2 | 5 ± 1 | 4 ± 1 |
| | NR | NR | 102 ± 32 | 139 ± 28 | NR | 79 ± 18 | 146 ± 47 |
| | 65 | 30 | 38 | 33 | 49 | 15 | 44 |
| | 5.9 | 7.5 | 6.3 | 5.6 | 6.1 | 3.1 | 10.9 |
NR, not reported.
Measurements were carried out in triplicate (n≥3) using a single batch of enzyme; KM values are the means of three independent measurements ± standard deviation. Standard deviation values for kcat did not exceed 10%.